 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF announced that its subsidiary Altum Pharmaceuticals Inc and Pontificia Universidad Católica de Chile have successfully completed the Phase 1 portion of Phase 1-2 randomized placebo-controlled trial IN2COVID in coronavirus patients with the companys inhaled interferon alpha-2b product, AP-003. The Vancouver, British Columbia-based company said that 18 healthy individuals were enrolled in the Phase 1 portion of the IN2COVID trial. 